2026 Q1 -tulosraportti
Vain PDF
14 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 547 | - | - | ||
| 15 | - | - | ||
| 10 772 | - | - | ||
| 100 | - | - | ||
| 16 354 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 94 106 | 94 106 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 94 106 | 94 106 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenStock Status In these cases where the pharmacies are sold out, it is because they had to empty their stock they had from Adrex; the pharmacies concerned must now register Weeco astrum10-10. Green Medical; available at 2 pharmacies. One is sold out. They have emptied the stock, with the oil from Adrex pharma. If they restock, it will be from Weeco pharma. Med can one stop: available at 4 pharmacies, that's 2 more than yesterday. Canngo. Sold out at 2 pharmacies. if Astrum comes back in stock, it will be from Weeco. The rest status Que K1000 I have inserted the different prices for Astrum10-10 that I could see today. prices on the different platforms that sell Astrum10-10 https://greenmedical.health/de/cannabis/extract/astrum_10_10_stenocare_cannabisextrakt-ausgewogen_thc_cbd On this platform you can see that Adrex is cheaper than Weeco. https://medcanonestop.com/medcan_product/adrex-astrum-cannabisextrakt-1010/https://medcanonestop.com/medcan_product/weeco-astrum-10-10/
·1 t sitten · Muokattu@3D... Can't you be so kind as to not involve me in your writings in a way that makes it seem as if I have contributed to your meaningless project..? I have NOT inserted prices on Astrum. I have merely informed you that Astrum can be obtained much cheaper than what you stated on several occasions.·1 t sittenDear K1000, I think we should agree that when you comment on the posts I write in the future, you ensure that it states that you do not want any comments from me, because then others who read your posts will know that when I do not comment, regardless of whether what you write is correct or not, it is because you have, in advance, requested no comment from me.- ·1 päivä sittenStock status Canngo: in stock There are 3 pharmacies that sell Astrum (It's only today that I found out the number of pharmacies) Now that the price has been asked about, this topic is also different from in Denmark. In Denmark, prescription medicine has the same price everywhere. But that's not the case in Germany. As I have stated several times, you need a prescription to get access to the price from most providers. but the few I can see are 3.33€ to 4.52€ (I read the following on Google) But we can indirectly find out if Stenocare earns more or less money per bottle sold. It is such in Germany that the price of a product that is prescription-only does not necessarily cost the same everywhere in Germany; it is up to the pharmacies to set the price of the products they sell. I have put it in bullet points and simplified it, because like everything else in Germany, it is complicated: It typically happens in such a way. - if few people buy the medical item, the item will be an order item and the price will be at the lowest level. - If enough people buy the item for it to be in stock, but no more than that, the price will be low, and slightly higher than if it is an order item. - If even more people buy the item, and there is a certain flow in the warehouse, the price will be slightly higher - If the item becomes very popular, the price will also be screwed up even higher. What can we use this for? Since Stenocare only gets money when the prescription is redeemed, we can calculate that in areas where there is a small flow, the price of Astrum10-10 is cheapest, and here Stenocare will get less money per. sold bottle. Where the flow is larger, we can expect Stenocare to get more money per. sold bottle there. As I remember it, Stenocare gets percentages and not a fixed price per. sold unit. Therefore, it is a greater advantage for Stenocare that Stenocare is settled with the end-users, and not with the distributor. (besides it being more accurate) Because the German system is structured in this way, Stenocare will never get into trouble in the German system if the price becomes very high. An example could be the much-discussed obesity preparations, where Novo was blamed for screwing up the price too high (I am describing the situation and not the product) Stenocare will get off scot-free because it is the pharmacies that raise the price, which they can do because it is the insurance companies that pay. Not the end-users, or the doctors, nor the public health insurance system. Because it is the insurance companies that pay, doctors are more willing to prescribe Astrum10-10 I should also mention that Astrum10-10 resembles the medicine doctors are trained in. which also contributes to doctors feeling comfortable prescribing Astrum10-10
- ·3 päivää sittenStock status I can confirm that it's going the right way, forward, steadily. New Green Medical - in stock Is nationwide - Can be obtained at two pharmacies, one in Berlin and the other in Düsseldorf CannabisApo24 - in stock·2 päivää sittenThanks K1000. You are right, it's per ml. I cannot find other prices, because most state the price when you have provided your prescription number. I haven't looked much into the price, because as I wrote, the pharmacy determines their own prices. As I have written earlier, the market is completely opaque, and one really has to go into detail to get a reasonable overview and to avoid duplicates. In my search to find pharmacies that sell Astrum10-10, I have found that a company can own the entire distribution chain. E.g., a pharmacy can be the main owner, and then that pharmacy can have 2 subsidiaries. One is the distributor and the other is what they call telemedicine; these are the ones who issue prescriptions online. For your information, there is still a big debate in Germany about whether telemedicine can continue.·2 päivää sittenYou yourself write that it's completely opaque, while at the same time you believe you can get an overview of an entire market by observing what's on the shelves in a couple of pharmacies, and that in a huge country like Germany. It's a bit like imagining you can get a precise picture of what the total bread market looks like by observing a couple of shelves in the local Netto. It's incomprehensible to me that you yourself cannot see that your method is so flawed that it has no value.
·3 päivää sittenI'll stick with it for a while longer as long as I believe in the product.
·2 päivää sittenAgreed. However, I give them the 2026 financial year to show that there is now progress. Should I keep them, they must not be extraordinary in 2027.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
14 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenStock Status In these cases where the pharmacies are sold out, it is because they had to empty their stock they had from Adrex; the pharmacies concerned must now register Weeco astrum10-10. Green Medical; available at 2 pharmacies. One is sold out. They have emptied the stock, with the oil from Adrex pharma. If they restock, it will be from Weeco pharma. Med can one stop: available at 4 pharmacies, that's 2 more than yesterday. Canngo. Sold out at 2 pharmacies. if Astrum comes back in stock, it will be from Weeco. The rest status Que K1000 I have inserted the different prices for Astrum10-10 that I could see today. prices on the different platforms that sell Astrum10-10 https://greenmedical.health/de/cannabis/extract/astrum_10_10_stenocare_cannabisextrakt-ausgewogen_thc_cbd On this platform you can see that Adrex is cheaper than Weeco. https://medcanonestop.com/medcan_product/adrex-astrum-cannabisextrakt-1010/https://medcanonestop.com/medcan_product/weeco-astrum-10-10/·1 t sitten · Muokattu@3D... Can't you be so kind as to not involve me in your writings in a way that makes it seem as if I have contributed to your meaningless project..? I have NOT inserted prices on Astrum. I have merely informed you that Astrum can be obtained much cheaper than what you stated on several occasions.·1 t sittenDear K1000, I think we should agree that when you comment on the posts I write in the future, you ensure that it states that you do not want any comments from me, because then others who read your posts will know that when I do not comment, regardless of whether what you write is correct or not, it is because you have, in advance, requested no comment from me.
- ·1 päivä sittenStock status Canngo: in stock There are 3 pharmacies that sell Astrum (It's only today that I found out the number of pharmacies) Now that the price has been asked about, this topic is also different from in Denmark. In Denmark, prescription medicine has the same price everywhere. But that's not the case in Germany. As I have stated several times, you need a prescription to get access to the price from most providers. but the few I can see are 3.33€ to 4.52€ (I read the following on Google) But we can indirectly find out if Stenocare earns more or less money per bottle sold. It is such in Germany that the price of a product that is prescription-only does not necessarily cost the same everywhere in Germany; it is up to the pharmacies to set the price of the products they sell. I have put it in bullet points and simplified it, because like everything else in Germany, it is complicated: It typically happens in such a way. - if few people buy the medical item, the item will be an order item and the price will be at the lowest level. - If enough people buy the item for it to be in stock, but no more than that, the price will be low, and slightly higher than if it is an order item. - If even more people buy the item, and there is a certain flow in the warehouse, the price will be slightly higher - If the item becomes very popular, the price will also be screwed up even higher. What can we use this for? Since Stenocare only gets money when the prescription is redeemed, we can calculate that in areas where there is a small flow, the price of Astrum10-10 is cheapest, and here Stenocare will get less money per. sold bottle. Where the flow is larger, we can expect Stenocare to get more money per. sold bottle there. As I remember it, Stenocare gets percentages and not a fixed price per. sold unit. Therefore, it is a greater advantage for Stenocare that Stenocare is settled with the end-users, and not with the distributor. (besides it being more accurate) Because the German system is structured in this way, Stenocare will never get into trouble in the German system if the price becomes very high. An example could be the much-discussed obesity preparations, where Novo was blamed for screwing up the price too high (I am describing the situation and not the product) Stenocare will get off scot-free because it is the pharmacies that raise the price, which they can do because it is the insurance companies that pay. Not the end-users, or the doctors, nor the public health insurance system. Because it is the insurance companies that pay, doctors are more willing to prescribe Astrum10-10 I should also mention that Astrum10-10 resembles the medicine doctors are trained in. which also contributes to doctors feeling comfortable prescribing Astrum10-10
- ·3 päivää sittenStock status I can confirm that it's going the right way, forward, steadily. New Green Medical - in stock Is nationwide - Can be obtained at two pharmacies, one in Berlin and the other in Düsseldorf CannabisApo24 - in stock·2 päivää sittenThanks K1000. You are right, it's per ml. I cannot find other prices, because most state the price when you have provided your prescription number. I haven't looked much into the price, because as I wrote, the pharmacy determines their own prices. As I have written earlier, the market is completely opaque, and one really has to go into detail to get a reasonable overview and to avoid duplicates. In my search to find pharmacies that sell Astrum10-10, I have found that a company can own the entire distribution chain. E.g., a pharmacy can be the main owner, and then that pharmacy can have 2 subsidiaries. One is the distributor and the other is what they call telemedicine; these are the ones who issue prescriptions online. For your information, there is still a big debate in Germany about whether telemedicine can continue.·2 päivää sittenYou yourself write that it's completely opaque, while at the same time you believe you can get an overview of an entire market by observing what's on the shelves in a couple of pharmacies, and that in a huge country like Germany. It's a bit like imagining you can get a precise picture of what the total bread market looks like by observing a couple of shelves in the local Netto. It's incomprehensible to me that you yourself cannot see that your method is so flawed that it has no value.
- ·3 päivää sittenI'll stick with it for a while longer as long as I believe in the product.·2 päivää sittenAgreed. However, I give them the 2026 financial year to show that there is now progress. Should I keep them, they must not be extraordinary in 2027.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 547 | - | - | ||
| 15 | - | - | ||
| 10 772 | - | - | ||
| 100 | - | - | ||
| 16 354 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 94 106 | 94 106 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 94 106 | 94 106 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
14 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenStock Status In these cases where the pharmacies are sold out, it is because they had to empty their stock they had from Adrex; the pharmacies concerned must now register Weeco astrum10-10. Green Medical; available at 2 pharmacies. One is sold out. They have emptied the stock, with the oil from Adrex pharma. If they restock, it will be from Weeco pharma. Med can one stop: available at 4 pharmacies, that's 2 more than yesterday. Canngo. Sold out at 2 pharmacies. if Astrum comes back in stock, it will be from Weeco. The rest status Que K1000 I have inserted the different prices for Astrum10-10 that I could see today. prices on the different platforms that sell Astrum10-10 https://greenmedical.health/de/cannabis/extract/astrum_10_10_stenocare_cannabisextrakt-ausgewogen_thc_cbd On this platform you can see that Adrex is cheaper than Weeco. https://medcanonestop.com/medcan_product/adrex-astrum-cannabisextrakt-1010/https://medcanonestop.com/medcan_product/weeco-astrum-10-10/·1 t sitten · Muokattu@3D... Can't you be so kind as to not involve me in your writings in a way that makes it seem as if I have contributed to your meaningless project..? I have NOT inserted prices on Astrum. I have merely informed you that Astrum can be obtained much cheaper than what you stated on several occasions.·1 t sittenDear K1000, I think we should agree that when you comment on the posts I write in the future, you ensure that it states that you do not want any comments from me, because then others who read your posts will know that when I do not comment, regardless of whether what you write is correct or not, it is because you have, in advance, requested no comment from me.
- ·1 päivä sittenStock status Canngo: in stock There are 3 pharmacies that sell Astrum (It's only today that I found out the number of pharmacies) Now that the price has been asked about, this topic is also different from in Denmark. In Denmark, prescription medicine has the same price everywhere. But that's not the case in Germany. As I have stated several times, you need a prescription to get access to the price from most providers. but the few I can see are 3.33€ to 4.52€ (I read the following on Google) But we can indirectly find out if Stenocare earns more or less money per bottle sold. It is such in Germany that the price of a product that is prescription-only does not necessarily cost the same everywhere in Germany; it is up to the pharmacies to set the price of the products they sell. I have put it in bullet points and simplified it, because like everything else in Germany, it is complicated: It typically happens in such a way. - if few people buy the medical item, the item will be an order item and the price will be at the lowest level. - If enough people buy the item for it to be in stock, but no more than that, the price will be low, and slightly higher than if it is an order item. - If even more people buy the item, and there is a certain flow in the warehouse, the price will be slightly higher - If the item becomes very popular, the price will also be screwed up even higher. What can we use this for? Since Stenocare only gets money when the prescription is redeemed, we can calculate that in areas where there is a small flow, the price of Astrum10-10 is cheapest, and here Stenocare will get less money per. sold bottle. Where the flow is larger, we can expect Stenocare to get more money per. sold bottle there. As I remember it, Stenocare gets percentages and not a fixed price per. sold unit. Therefore, it is a greater advantage for Stenocare that Stenocare is settled with the end-users, and not with the distributor. (besides it being more accurate) Because the German system is structured in this way, Stenocare will never get into trouble in the German system if the price becomes very high. An example could be the much-discussed obesity preparations, where Novo was blamed for screwing up the price too high (I am describing the situation and not the product) Stenocare will get off scot-free because it is the pharmacies that raise the price, which they can do because it is the insurance companies that pay. Not the end-users, or the doctors, nor the public health insurance system. Because it is the insurance companies that pay, doctors are more willing to prescribe Astrum10-10 I should also mention that Astrum10-10 resembles the medicine doctors are trained in. which also contributes to doctors feeling comfortable prescribing Astrum10-10
- ·3 päivää sittenStock status I can confirm that it's going the right way, forward, steadily. New Green Medical - in stock Is nationwide - Can be obtained at two pharmacies, one in Berlin and the other in Düsseldorf CannabisApo24 - in stock·2 päivää sittenThanks K1000. You are right, it's per ml. I cannot find other prices, because most state the price when you have provided your prescription number. I haven't looked much into the price, because as I wrote, the pharmacy determines their own prices. As I have written earlier, the market is completely opaque, and one really has to go into detail to get a reasonable overview and to avoid duplicates. In my search to find pharmacies that sell Astrum10-10, I have found that a company can own the entire distribution chain. E.g., a pharmacy can be the main owner, and then that pharmacy can have 2 subsidiaries. One is the distributor and the other is what they call telemedicine; these are the ones who issue prescriptions online. For your information, there is still a big debate in Germany about whether telemedicine can continue.·2 päivää sittenYou yourself write that it's completely opaque, while at the same time you believe you can get an overview of an entire market by observing what's on the shelves in a couple of pharmacies, and that in a huge country like Germany. It's a bit like imagining you can get a precise picture of what the total bread market looks like by observing a couple of shelves in the local Netto. It's incomprehensible to me that you yourself cannot see that your method is so flawed that it has no value.
- ·3 päivää sittenI'll stick with it for a while longer as long as I believe in the product.·2 päivää sittenAgreed. However, I give them the 2026 financial year to show that there is now progress. Should I keep them, they must not be extraordinary in 2027.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 547 | - | - | ||
| 15 | - | - | ||
| 10 772 | - | - | ||
| 100 | - | - | ||
| 16 354 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 94 106 | 94 106 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 94 106 | 94 106 | 0 | 0 |